Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma

Abstract excerpt

PURPOSE: Patients with macroscopic stage III melanoma represent a heterogeneous cohort with average 5-year overall survival rates of <30%. With current algorithms, it is not possible to predict which patients will achieve longer-term survival. We hypothesized that molecular profiling could be used to identify prognostic groups within patients with stage III melanoma while also providing a greater understanding of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cutaneous Melanoma Detection and Management
• Share to Glioma Diagnosis and Treatment
• Share to Melanoma and MAPK Pathways